Is Egrifta (Tesamorelin) Legal in New York?

HealthRX.com

Egrifta is FDA-approved, but New York rules are separate

Print or save as PDF

See the public record for Tesamorelin

  • FDA status / Approved prescription drug, application BLA 022505, first approved November 10, 2010 [1]
  • Current labels / Egrifta SV 2 mg vial and Egrifta WR 11.6 mg vial, both dated July 29, 2026 [2][3]
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2][3]
  • Not approved for / Weight loss; the label calls the effect weight-neutral [2]
  • Compounding / Not on FDA's significant-safety-risk list or its state-licensed pharmacy or outsourcing facility category lists [4][5][6]
  • HHS peptide policy / Not one of the six peptides in the October 2026 draft enforcement-discretion policy [7][8]
  • Sport / WADA names it in S2.2.4 and prohibits it at all times [9][10]

What does FDA approval mean for New York?

Egrifta was first approved on November 10, 2010, under BLA 022505 [1]. Drugs@FDA lists the 1 mg and 2 mg vials as prescription products [1]. The current labels are Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026 [2][3].

FDA approval makes Egrifta a federally approved prescription drug. State-level requirements in New York are a separate question from FDA approval.

Questions worth asking

Choose the questions you want to keep

What is it approved to treat?

The only approved use is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2][3]. The label adds limits: long-term cardiovascular safety has not been established, the risk and benefit of continuing should be considered in patients who have not had a reduction in visceral adipose tissue, and it is not indicated for weight loss because its effect on weight is neutral [2]. The label also says there are no data that it improves adherence to antiretroviral therapy [2].

Use in people without HIV lipodystrophy is outside the label, including use for general fat loss, anti-aging or muscle building [2].

Can tesamorelin be compounded?

Tesamorelin is not on FDA's list of bulk substances that may present significant safety risks; that list is dated April 22, 2026 [4]. It also appears in no category of FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, or of FDA's list for outsourcing facilities, updated March 21, 2025 [5][6]. So FDA has made no category-based statement about compounding it [4][5][6].

Tesamorelin is also not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 [7][8]. It is already a component of an FDA-approved drug, Egrifta [1][2]. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness or quality before they are marketed [8].

Is tesamorelin legal in sport?

WADA's Prohibited List names tesamorelin in S2.2.4, under growth hormone releasing factors (GHRH and its analogues) [9]. It is prohibited at all times, in and out of competition [9]. It is on the 2026 List in force since January 1, 2026, and remains on the 2027 List [9][10].

Is Egrifta (tesamorelin) legal in New York?
Egrifta is an FDA-approved prescription drug, first approved on November 10, 2010, for excess abdominal fat in HIV-infected adults with lipodystrophy [1][2]. It is available only as a prescription product [1].
Is compounded tesamorelin legal?
Compounded drugs are not FDA-approved [8]. Tesamorelin is not on FDA's significant-safety-risk list and appears in no category of the state-licensed pharmacy or outsourcing facility lists [4][5][6]. It is also not one of the six peptides in the October 2026 HHS draft policy [7][8].
Is tesamorelin banned in sports?
Yes for WADA-governed sport. WADA names tesamorelin in S2.2.4 and prohibits it at all times, in and out of competition [9][10].
What is the approved dose?
The Egrifta SV label gives 1.4 mg subcutaneously once daily, and the Egrifta WR label gives 1.28 mg once daily. The labels say the two are not substitutable [2][3].
Show all 10 referencesHide references
  1. Drugs@FDA: FDA-Approved Drugs.
  2. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  3. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. Official web page.
  8. Official web page.
  9. World Anti-Doping Agency.
  10. World Anti-Doping Agency.
Evidence overview for Is Egrifta (Tesamorelin) Legal in New York?